Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
"Antigen Expression by Dendritic Cells Correlates with the Therapeutic Effectiveness of a Model Recombinant Poxvirus Tumor Vaccine."
May 26th, 1997
According to the authors' abstract of an article published in Proceedings of the National Academy of Sciences of the United States of America, "Recombinant poxviruses encoding tumor-associated antigens (TAA) are attractive as candidate cancer vaccines. Their effectiveness, however, will depend upon expression of the TAA in appropriate antigen-presenting cells. We have used a murine model in which the TAA is beta-galactosidase (beta-gal) and a panel of recombinant vaccinia viruses (rVV) in which beta-gal was expressed under early or late promoters at levels that varied over 500-fold during productive infections in tissue culture cells. Remarkably, only those rVV employing early promoters...
Source: Cancer Weekly (1997-05-26)
|
|
Advertisement |
|
|
